The European Medicines Agency’s (EMA’) human medicines committee (CHMP) has recommended two new medicines and three ...

In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at up-to-date safety data on Leqembi (lecanemab) at its next meeting in ...

The Scientific Advisory Group (SAG) has been called in to assist the EMA’s CHMP ... opinions within the CHMP on clinical grounds. Eisai noted in a statement that the SAG meeting will take ...

Therapeutics announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a ...

Princeton: Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on Thursday recommended against marketing authorization for Eli Llilly's Alzheimer's drug Kisunla ...

EMA committee recommends approval of Bristol Myers Squibb’s subcutaneous formulation of Opdivo across multiple solid tumour indications: Princeton, New Jersey Monday, March 31, ...

The European Medicines Agency’s Committee for Medicinal Products for Human ... Lilly will seek re-examination by CHMP, the company noted. “Europeans living with early symptomatic Alzheimer’s disease ...

Eli Lilly, which is seeking European approval of Kisunla for the treatment of early symptomatic Alzheimer's, said it will seek re-examination by CHMP. The Indianapolis drugmaker said it remains ...